Skip to main content
. Author manuscript; available in PMC: 2024 Apr 12.
Published in final edited form as: Sci Transl Med. 2023 Sep 20;15(714):eadi7244. doi: 10.1126/scitranslmed.adi7244

Fig. 1. TP63 fusions promote lymphoma growth in vitro and in vivo.

Fig. 1.

(A) Schematic of fusions TBL1XR1, FOXK2, BCL6, TP63, ΔNp63, TBL1XR1::TP63, FOXK2::TP63 and BCL6::TP63. Different colors show different domains. (B) Cell viability of TCL cell lines treated with shTP63 or shSeed. (C) Western blot analysis for TBL1XR1::TP63 in Cas9-SMZ1-sgwtTP63 cells expressing Dox-inducible shSeed or shTP63 treated with or without Dox for four days. (D) Cell proliferation assay of cells from (C) using CellTiter-Glo (CTG). (E) Tumor volume at the indicated timepoint after subcutaneous implantation of Cas9-SMZ1-sgwtTP63 cells with Dox-inducible shTP63 into mice (n=5 per group). The red arrow indicates the beginning of treatment with Dox or vehicle in vivo. (F) Rescue experiment of SMZ1 cells expressing shSeed or shTP63 with empty vector (EV) or TBL1XR1::TP63 expressing vector. (G) The proliferation of Ba/F3 cells expressing EV or TBL1XR1::TP63 cultured in the presence of the indicated concentrations of mIL-3 measured using CTG. Data are normalized to the empty vector (EV) group. (H) Western blot analysis using an anti-TP63 antibody in Cas9-SMZ1-sgwtTP63-shTP63 cells expressing Dox-inducible BCL6::TP63 fusion. Cells were treated with or without Dox for four days. (I) Cell proliferation assay of cells in (H) using CTG. (J, K) Normalized CRISPR score (NCS) of each sgRNA (dots) and the smoothed score (line) of the pooled TBL1XR1 and TP63 (J) and TBL1XR1::TP63 (K) survival screen on day 30 in SMZ1-Cas9+ cells.

All data unless specified are presented as mean ± SD or ±SEM, n=3 biological replicates. * P<0.05, *** P<0.001 or **** P<0.0001 as compared between indicated groups (Student’s t-test).

HHS Vulnerability Disclosure